During the past decade, Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe conducted 89 clinical trials. In the 10-year time frame, 89 clinical trials started and 44 clinical trials were completed, i.e. on average, 49.4% percent of trials that started reached the finish line to date. In the past 5 years, 52 clinical trials started and 34 clinical trials were completed. i.e. 65.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe" #1 sponsor was "Celgene" with 14 trials, followed by "Janssen Research & Development, LLC" with 11 trials sponsored, "Pfizer" with 8 trials sponsored, "Boehringer Ingelheim" with 6 trials sponsored and "Gilead Sciences" with 6 trials sponsored. Other sponsors include 67 different institutions and companies that sponsored additional 51 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe" #1 collaborator was "AstraZeneca" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "Pharmacyclics LLC." with 2 trials as a collaborator. Other collaborators include 60 different institutions and companies that were collaborators in the rest 70 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe" are "Carcinoma, Non-Small-Cell Lung" (9 trials), "Breast Cancer" (7 trials), "Multiple Myeloma" (7 trials), "Chronic Lymphocytic Leukemia" (4 trials) and "Leukemia, Myeloid, Acute" (4 trials). Many other conditions were trialed in "Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe" in a lesser frequency.

Most popular intervention types in "Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe" are "Drug" (101 trials), "Biological" (16 trials), "Other" (7 trials), "Device" (4 trials) and "Radiation" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Carboplatin" (11 trials), "Lenalidomide" (8 trials), "Dexamethasone" (7 trials) and "Docetaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe" are 108 trials for "All" genders, 6 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe". undefined are not yet recruiting, 31 are recruiting, 30 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 41 completed trials in Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, 8 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 81 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".